MLAB 📈 Mesa Laboratories - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US59064R1095

MLAB: Life Sciences Tools, Quality Control Products, Laboratory Services

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado. Web URL: https://www.mesalabs.com

Additional Sources for MLAB Stock

MLAB Stock Overview

Market Cap in USD 636m
Sector Technology
Industry Scientific & Technical Instruments
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception 1995-01-25

MLAB Stock Ratings

Growth 5y -47.7%
Fundamental -14.3%
Dividend 34.5%
Rel. Strength Industry 482
Analysts 3.5/5
Fair Price Momentum 117.68 USD
Fair Price DCF 170.43 USD

MLAB Dividends

Dividend Yield 12m 0.48%
Yield on Cost 5y 0.26%
Annual Growth 5y 0.00%
Payout Consistency 96.2%

MLAB Growth Ratios

Growth Correlation 3m -15.9%
Growth Correlation 12m 66.6%
Growth Correlation 5y -79.8%
CAGR 5y -11.60%
CAGR/Mean DD 5y -0.33
Sharpe Ratio 12m 0.62
Alpha 5.39
Beta 0.77
Volatility 54.89%
Current Volume 141.8k
Average Volume 20d 44.5k
What is the price of MLAB stocks?
As of December 21, 2024, the stock is trading at USD 132.08 with a total of 141,805 shares traded.
Over the past week, the price has changed by +3.54%, over one month by +34.15%, over three months by +2.87% and over the past year by +29.95%.
Is Mesa Laboratories a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Mesa Laboratories is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.29 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MLAB as of December 2024 is 117.68. This means that MLAB is currently overvalued and has a potential downside of -10.9%.
Is MLAB a buy, sell or hold?
Mesa Laboratories has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold MLAB.
  • Strong Buy: 2
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • Strong Sell: 1
What are the forecast for MLAB stock price target?
According to ValueRays Forecast Model, MLAB Mesa Laboratories will be worth about 128.2 in December 2025. The stock is currently trading at 132.08. This means that the stock has a potential downside of -2.92%.
Issuer Forecast Upside
Wallstreet Target Price 133.3 0.9%
Analysts Target Price 139 5.2%
ValueRay Target Price 128.2 -2.9%